< Back to Press

ASCENSIA DIABETES CARE TAKES OVER DISTRIBUTION OF EVERSENSE^® XL CONTINUOUS GLUCOSE MONITORING SYSTEM IN SELECTED EUROPEAN MARKETS

Basel, Switzerland

Ascensia Diabetes Care, a leading global diabetes care company, has today entered the continuous glucose monitoring market in Europe as it takes over the distribution of Senseonics’ Eversense^® XL, the world’s first and only long-term implantable continuous glucose monitoring (CGM) system, in selected European markets. This follows the signing of a commercialization and distribution agreement in August 2020 with Senseonics Inc., which enables Ascensia to offer Eversense^® products, over a 5-year period, in selected countries. As part of this agreement, Ascensia has today taken over distribution of Eversense^® XL in Germany, Switzerland, Italy, Spain, The Netherlands and Poland. In the US, Ascensia is already providing sales support for the Eversense^® 90-day implantable CGM system, and will take over increased commercialization from April 1, 2021.

As the only CGM that provides continuous glucose readings for up to 180 days with a single sensor, the Eversense XL is professionally inserted under the skin giving users the freedom from weekly or bi-weekly self-insertions. Designed with the patient in mind, the Eversense^® system has a removable transmitter that provides discretion and flexibility, with the added reassurance of on-body vibratory alerts, when the transmitter is attached to the skin over the sensor, to inform  users when their glucose level is outside their low or high setting.  The system is accurate throughout its sensor life with a MARD of 9.4%¹. The Eversense^® Mobile app for real-time monitoring and management, enables users to view their data on their smart phone and share retrospective data from the Data Management System with their HCPs. In addition, through the accompanying Eversense^® NOW caregiver app, Eversense^® users can authorize up to five people to remotely view a user’s real-time readings and alerts.

Rob Schumm, President of Ascensia Diabetes Care commented: “At Ascensia Diabetes Care, our fundamental goal is to simplify and improve the lives of people living with diabetes. Entering into the CGM market through our alliance with Senseonics is a critical component of this. Each person with diabetes has different needs and having choice in the selection of diabetes technology to meet those needs is critical. Being able to offer Eversense products alongside our existing blood glucose monitoring portfolio, therefore, allows us to provide a more comprehensive range of glucose monitoring technologies to suit the specific individual needs of people with diabetes.”

Claudia Geis, Head of CGM Business Unit at Ascensia Diabetes Care continued: “We believe that an implantable CGM sensor that lasts for up to 180 days can be a major benefit for people with diabetes by providing enhanced convenience and improved patient experience. The system is also known to be one of the most accurate CGMs on the market and has unique product features that bring both peace of mind and flexibility to users, along with discretion. Together, this makes Eversense a valuable technology option for HCPs and people with diabetes alike for the monitoring and provision of information to improve the management of diabetes.”

For more information about Eversense XL please visit: www.ascensia.com/eversense.

ENDS

Notes for Editors

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world renowned CONTOUR^® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense^® continuous glucose monitoring systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of the PHC Group and was established in 2016 through the sale of Bayer Diabetes Care to PHC Holdings (formerly Panasonic Healthcare). Ascensia products are sold in more than 125 countries. Ascensia has around 1,700 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com 

©2020 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

For more information, please contact:

Annabel Watson                                                                       
Global Communications Manager
annabel.watson@ascensia.com 
+41 76 432 46 25                                                                           

References

1. Aronson R et al. First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes. Diabetes Obes Metab 2019;21(7):1689-1694